Vident Investment Advisory LLC bought a new position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 8,065 shares of the biopharmaceutical company’s stock, valued at approximately $1,132,000.

Several other hedge funds also recently made changes to their positions in the company. Rathbone Brothers plc lifted its holdings in Alexion Pharmaceuticals by 2.5% in the second quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 50 shares during the period. Geneva Advisors LLC lifted its holdings in Alexion Pharmaceuticals by 0.7% in the second quarter. Geneva Advisors LLC now owns 11,408 shares of the biopharmaceutical company’s stock valued at $1,388,000 after buying an additional 82 shares during the period. Evercore Wealth Management LLC lifted its holdings in Alexion Pharmaceuticals by 8.1% in the second quarter. Evercore Wealth Management LLC now owns 1,665 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 125 shares during the period. Wealthsource Partners LLC lifted its holdings in Alexion Pharmaceuticals by 4.4% in the second quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock valued at $365,000 after buying an additional 126 shares during the period. Finally, Penserra Capital Management LLC lifted its holdings in Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 144 shares during the period. Institutional investors own 94.33% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $113.54 on Thursday. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The company has a market cap of $25,370.00, a P/E ratio of 22.88, a price-to-earnings-growth ratio of 1.22 and a beta of 1.18.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. During the same quarter in the prior year, the firm earned $1.23 earnings per share. The firm’s revenue was up 7.5% compared to the same quarter last year. equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current fiscal year.

Several brokerages recently weighed in on ALXN. Credit Suisse Group restated a “buy” rating and issued a $166.00 price objective on shares of Alexion Pharmaceuticals in a report on Tuesday. Leerink Swann restated a “buy” rating and issued a $169.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, December 6th. TheStreet lowered shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Finally, Royal Bank of Canada increased their price objective on shares of Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $155.47.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/vident-investment-advisory-llc-invests-1-13-million-in-alexion-pharmaceuticals-inc-alxn/1762675.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.